Imigran (Sumatriptan)

Sumatriptan works by selectively stimulating serotonin 5‑HT1B and 5‑HT1D receptors on cranial blood vessels and trigeminal nerve endings. This leads to vasoconstriction of dilated intracranial vessels and inhibition of pro‑inflammatory neuropeptide release, interrupting the migraine cascade.

The dose and administration schedule of Imigran are determined by the prescribing healthcare professional based on the patient’s clinical condition, severity of migraine, and prior response to therapy. Patients should follow the prescriber’s instructions precisely.

Safety data for sumatriptan in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To order Imigran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Imigran belongs to the triptan class, which provides rapid, targeted relief of migraine by acting on serotonin receptors. Compared with non‑specific analgesics or NSAIDs, triptans address the underlying vascular and neurogenic mechanisms of migraine, often achieving faster and more complete symptom resolution.

Imigran should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If the temperature exceeds the recommended range, discard the product according to local regulations.

Imigran is supplied as a subcutaneous injection. The dose is typically administered by a healthcare professional using a sterile syringe, injected into the fatty tissue of the abdomen or thigh. Patients should be instructed on proper technique and advised to seek medical assistance if they experience any adverse reactions.

The most serious risks include chest pain or coronary vasospasm, which may signal cardiac ischemia, and serotonin syndrome, a potentially life‑threatening condition that can occur when sumatriptan is combined with other serotonergic agents. Immediate medical attention is required if these symptoms appear.

Imigran is contraindicated in patients with known hypersensitivity to sumatriptan, a history of ischemic heart disease, uncontrolled hypertension, severe hepatic impairment, or those who have experienced coronary vasospasm with previous triptan use. It should also be avoided in patients taking ergot alkaloids or monoamine oxidase inhibitors.